

THE DIFFERENCE OF ONE INNOVATIVE PARTNER IN ADVANCING THE WORLD OF HEALTH

THE DEADLY CASE OF ANTIMICROBIAL RESISTANCE (AMR)

Even non-scientists are familiar with the term 'superbug', a term used in everyday speech to describe micro-organisms such as methicillin-resistant *Staphylococcus aureus* (MRSA) which have become resistant to conventional antimicrobial treatments. Globally, MRSA and other similarly resistant superbugs have become a major cause of preventable deaths. Indeed, with the projected rise of AMR it is possible that we are heading towards the end of the antibiotic era.

The 28th European Congress of Clinical Microbiology and Infectious Diseases was hosted in the Feria de Madrid at the end of April. BD Life Sciences was a significant presence at the convention. In keeping with our commitment to help combat AMR, we hosted a symposium entitled, 'Fighting antimicrobial resistance: diagnostic solutions that lead to an appropriate use of antibiotics and help reduce the spread of AMR.' The meeting included a series of talks from experts in microbiology and covered topics on blood culture and AMR, laboratory strategies in the fight against AMR and the role of Automation in tackling AMR.

BD takes the AMR issue seriously. As well as developing products that are vital weapons in the war against AMR, we are a global presence in terms of health and policy development, collaborating with others to tackle this important and time-sensitive issue. As David Hickey, President of BD Diagnostic Systems (USA) said in his introduction to the symposium,

'We do not have to accept that AMR will become the deadliest problem facing human health: with effective processes, communication and tools we can make a difference.'

Learn more at amr.bd.com

BD Switzerland Sàrl, Terre-Bonne Park - A4, Route de Crassier 17, 1262 Eysins, Switzerland

bd.com

